Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma

By afschroeder • May 21, 2026

Piperno-Neumann S, Rutkowski P, Hassel JC, Butler MO, Schlaak M, Sullivan RJ, Dummer R, Kirkwood JM, Sacco JJ, Shoushtari AN, Piulats JM, Salama AKS, Orloff MM, Joshua AM, Ochsenreither S, Gastaud L, Curti BD, Demidov LV, Milhem MM, Chmielowski B, Kendra KL, Ascierto PA, Bernicker EH, Carvajal RD, Collins L, Lockwood S, Patel JM, Hamid OA, Baurain JF, Nathan PD. Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma. Ann Oncol. 2026 May 19:S0923-7534(26)00879-3. doi: 10.1016/j.annonc.2026.05.695. Epub ahead of print. PMID: 42162665.

Tags: circulating tumor DNA, Hematology/Oncology, metastatic uveal melanoma, overall survival, Publications, T cell engager, T cell receptor bispecific, tebentafusp

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3

Nooka AK, Strouse C, Larson SM, Lesokhin A, Varshavsky-Yanovsky A, Vesole DH, Koehne G, Soussou E, Sullivan ST, Cheng J, Raje N. Efficacy and safety[...]

mGEM: multigraph estimation models for pattern analysis

Landeros A, Krishnan D, Lange K, Sehl M. mGEM: multigraph estimation models for pattern analysis. BMC Bioinformatics. 2026 May 20. doi: 10.1186/s12859-026-06467-3. Epub ahead of[...]

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study

Muffly L, Frey NV, Roloff GW, Park JH, Dholaria B, Advani AS, Bachanova V, Cassaday RD, Daunov M, Dykes KC, Irizarry Gatell V, Grunwald MR,[...]